PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Retailers
- Sub-Industry: Health Care Distributors
- Symbol: NYSE:PMC
- CUSIP: 71714F10
- Web: www.pharmerica.com
- Market Cap: $905.56 million
- Outstanding Shares: 31,121,000
- 50 Day Moving Avg: $28.94
- 200 Day Moving Avg: $25.67
- 52 Week Range: $19.20 - $29.40
Sales & Book Value:
- Trailing P/E Ratio: 39.50
- Foreward P/E Ratio: 13.43
- P/E Growth: 1.54
- Annual Revenue: $2.21 billion
- Price / Sales: 0.41
- Book Value: $17.89 per share
- Price / Book: 1.63
- EBIDTA: $133 million
- Net Margins: 1.05%
- Return on Equity: 10.94%
- Return on Assets: 4.84%
- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 2.57%
- Quick Ratio: 1.79%
- Average Volume: 463,161 shs.
- Beta: 0.84
- Short Ratio: 3.94
Frequently Asked Questions for Pharmerica Corporation (NYSE:PMC)
What is Pharmerica Corporation's stock symbol?
Pharmerica Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "PMC."
How were Pharmerica Corporation's earnings last quarter?
Pharmerica Corporation (NYSE:PMC) released its earnings results on Wednesday, August, 2nd. The company reported $0.47 EPS for the quarter, meeting the consensus estimate of $0.47. The firm had revenue of $592 million for the quarter, compared to analyst estimates of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The business's quarterly revenue was up 13.9% compared to the same quarter last year. During the same period last year, the firm earned $0.47 EPS. View Pharmerica Corporation's Earnings History.
When will Pharmerica Corporation make its next earnings announcement?
Where is Pharmerica Corporation's stock going? Where will Pharmerica Corporation's stock price be in 2017?
3 brokers have issued 12-month price targets for Pharmerica Corporation's stock. Their predictions range from $29.25 to $29.25. On average, they expect Pharmerica Corporation's share price to reach $29.25 in the next twelve months. View Analyst Ratings for Pharmerica Corporation.
Are investors shorting Pharmerica Corporation?
Pharmerica Corporation saw a increase in short interest in August. As of August 15th, there was short interest totalling 1,211,533 shares, an increase of 58.0% from the July 31st total of 766,695 shares. Based on an average trading volume of 1,419,804 shares, the days-to-cover ratio is presently 0.9 days. Currently, 4.1% of the company's shares are sold short.
Who are some of Pharmerica Corporation's key competitors?
Some companies that are related to Pharmerica Corporation include Theravance Biopharma (TBPH), Teladoc (TDOC), Impax Laboratories (IPXL), Amedisys (AMED), Cambrex Corporation (CBM), Owens & Minor (OMI), Akcea Therapeutics (AKCA), MyoKardia (MYOK), HMS Holdings Corp (HMSY), Tenet Healthcare Corporation (THC), Emergent Biosolutions (EBS), Immunomedics (IMMU), Radius Health (RDUS), Healthways (TVTY), Repligen Corporation (RGEN), Innoviva (INVA), Pacira Pharmaceuticals (PCRX) and Quidel Corporation (QDEL).
Who are Pharmerica Corporation's key executives?
Pharmerica Corporation's management team includes the folowing people:
- Geoffrey G. Meyers, Independent Chairman of the Board
- Gregory S. Weishar, Chief Executive Officer, Director
- Suresh Vishnubhatla, Executive Vice President - Long-term Care Operations
- Berard E. Tomassetti, Senior Vice President, Chief Accounting Officer
- Thomas A. Caneris, Senior Vice President, General Counsel, Secretary
- Robert A. McKay, Senior Vice President - Purchasing and Trade Relations
- Frank E. Collins Esq., Independent Director
- W. Robert Robert Dahl Jr., Independent Director
- Marjorie W. Dorr, Independent Director
- Patrick G. LePore, Independent Director
Who owns Pharmerica Corporation stock?
Pharmerica Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.58%), Dimensional Fund Advisors LP (8.41%), Vanguard Group Inc. (5.30%), Boston Partners (4.43%), Victory Capital Management Inc. (4.16%) and FMR LLC (3.68%). Company insiders that own Pharmerica Corporation stock include Mark Lindemoen and Robert A Mckay. View Institutional Ownership Trends for Pharmerica Corporation.
Who sold Pharmerica Corporation stock? Who is selling Pharmerica Corporation stock?
Pharmerica Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, American Century Companies Inc., Ameriprise Financial Inc., Systematic Financial Management LP, Prudential PLC, Citadel Advisors LLC, BlackRock Inc. and Prudential Financial Inc.. View Insider Buying and Selling for Pharmerica Corporation.
Who bought Pharmerica Corporation stock? Who is buying Pharmerica Corporation stock?
Pharmerica Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Victory Capital Management Inc., Boston Partners, Vanguard Group Inc., Chicago Equity Partners LLC, Brandywine Global Investment Management LLC, Algert Global LLC and Northern Trust Corp. View Insider Buying and Selling for Pharmerica Corporation.
How do I buy Pharmerica Corporation stock?
Shares of Pharmerica Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharmerica Corporation's stock price today?
MarketBeat Community Rating for Pharmerica Corporation (NYSE PMC)MarketBeat's community ratings are surveys of what our community members think about Pharmerica Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pharmerica Corporation stock can currently be purchased for approximately $29.15.
Consensus Ratings for Pharmerica Corporation (NYSE:PMC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$29.25 (0.34% upside)|
Analysts' Ratings History for Pharmerica Corporation (NYSE:PMC)
(Data available from 9/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/9/2017||Barrington Research||Downgrade||Outperform -> Underperform||Low|
|8/4/2017||Credit Suisse Group||Downgrade||Outperform -> Neutral||$29.00 -> $29.25||Low|
|6/7/2016||Bank of America Corporation||Initiated Coverage||Buy||$32.00||N/A|
|2/29/2016||Barclays PLC||Lower Price Target||Underweight||$27.00 -> $22.00||N/A|
|12/30/2015||Cowen and Company||Reiterated Rating||Buy||$39.00 -> $41.00||N/A|
Earnings History for Pharmerica Corporation (NYSE:PMC)Earnings History by Quarter for Pharmerica Corporation (NYSE PMC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||$0.47||$0.47||$592.96 million||$592.00 million||View||N/A|
|5/10/2017||Q1 2017||$0.40||$0.42||$536.85 million||$566.80 million||View||N/A|
|2/24/2017||Q416||$0.51||$0.58||$525.22 million||$534.40 million||View||Listen|
|11/9/2016||Q316||$0.51||$0.44||$530.01 million||$512.60 million||View||Listen|
|8/9/2016||Q216||$0.47||$0.47||$508.31 million||$519.60 million||View||Listen|
|5/6/2016||Q116||$0.43||$0.45||$509.45 million||$524.50 million||View||Listen|
|2/26/2016||Q415||$0.41||$0.45||$506.40 million||$520.60 million||View||Listen|
|11/6/2015||Q315||$0.36||$0.39||$480.35 million||$498.80 million||View||Listen|
|8/7/2015||Q215||$0.33||$0.37||$491.66 million||$497.50 million||View||Listen|
|5/7/2015||Q115||$0.43||$0.48||$500.95 million||$511.60 million||View||Listen|
|3/2/2015||Q414||$0.43||$0.45||$491.99 million||$523.50 million||View||Listen|
|11/6/2014||Q314||$0.40||$0.45||$439.63 million||$470.20 million||View||Listen|
|8/5/2014||Q214||$0.36||$0.40||$432.70 million||$448.60 million||View||Listen|
|5/1/2014||Q114||$0.33||$0.37||$417.76 million||$452.20 million||View||Listen|
|2/28/2014||Q413||$0.38||$0.44||$421.16 million||$433.20 million||View||Listen|
|11/5/2013||Q313||$0.32||$0.49||$398.02 million||$442.00 million||View||Listen|
|8/2/2013||Q2 2013||$0.34||$0.44||$414.15 million||$458.50 million||View||Listen|
|5/1/2013||Q1 2013||$0.34||$0.46||$435.10 million||$439.80 million||View||Listen|
|2/7/2013||Q4 2012||$0.29||$0.12||$432.43 million||$433.20 million||View||Listen|
|11/1/2012||Q312||$0.30||$0.33||$446.36 million||$442.00 million||View||N/A|
Earnings Estimates for Pharmerica Corporation (NYSE:PMC)
2017 EPS Consensus Estimate: $1.88
2018 EPS Consensus Estimate: $2.12
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Pharmerica Corporation (NYSE:PMC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pharmerica Corporation (NYSE:PMC)
Insider Ownership Percentage: 5.04%Insider Trades by Quarter for Pharmerica Corporation (NYSE:PMC)
Institutional Ownership Percentage: 92.15%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/2/2015||Robert A Mckay||SVP||Sell||2,993||$34.42||$103,019.06|| |
|11/11/2015||Mark Lindemoen||SVP||Sell||3,790||$34.71||$131,550.90|| |
|6/16/2015||Robert A Mckay||SVP||Sell||7,000||$32.75||$229,250.00|| |
|6/3/2015||Gregory S Weishar||CEO||Sell||104,150||$32.63||$3,398,414.50|| |
|6/1/2015||Mark Lindemoen||SVP||Sell||4,500||$33.27||$149,715.00|| |
|3/12/2015||Berard Tomassetti||CAO||Sell||3,344||$26.44||$88,415.36|| |
|3/12/2015||Thomas A Caneris||SVP||Sell||7,495||$26.52||$198,767.40|| |
|3/6/2015||Robert A Mckay||SVP||Sell||20,000||$26.74||$534,800.00|| |
|8/8/2014||Robert A Oakley||Director||Sell||8,399||$26.55||$222,993.45|| |
|5/13/2014||Thomas Caneris||SVP||Sell||12,192||$28.60||$348,691.20|| |
|3/14/2014||Gregory Weishar||CEO||Sell||60,000||$26.27||$1,576,200.00|| |
|3/13/2014||Robert Mckay||SVP||Sell||18,646||$26.08||$486,287.68|| |
|3/12/2014||Berard Tomassetti||CAO||Sell||3,812||$25.22||$96,138.64|| |
|3/6/2014||Thomas Caneris||SVP||Sell||14,357||$25.60||$367,539.20|| |
|11/22/2013||Thomas Gerrity||Director||Sell||3,271||$20.56||$67,251.76|| |
|11/15/2013||Berard Tomassetti||CAO||Sell||4,097||$20.55||$84,193.35|| |
|5/30/2013||Berard Tomassetti||CAO||Sell||9,724||$15.68||$152,472.32|| |
Headline Trends for Pharmerica Corporation (NYSE:PMC)
Latest Headlines for Pharmerica Corporation (NYSE:PMC)
Pharmerica Corporation (PMC) Chart for Saturday, September, 23, 2017